Chronic lymphocytic leukemia driven by paradoxical ERK activation during BRAF inhibitor treatment

Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from the patient while being under BRAF inhibition versus CD14+ germline control cells (>90% purity). No alterations that could be linked to aberrant RAS activity or paradoxical RAF/MEK/ERK signaling could be identified in the CLL, which shows characteristic copy number alterations.

Request Access

Studies are experimental investigations of a particular phenomenon. e.g. case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients. Click on one of the Study IDs below to find out more.

Study ID Study Title Study Type
EGAS00001000948 Other
ID File Type Size Located in Quality Control
EGAF00000603178 fastq.gz 4.6 GB
EGAF00000603179 fastq.gz 5.0 GB
EGAF00000603180 fastq.gz 4.0 GB
EGAF00000603181 fastq.gz 4.3 GB
Request Access